Encompass Health (EHC) EBITDA (2009 - 2026)

Encompass Health has reported EBITDA for 18 years, with the latest figure at $59.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 69.62% year-over-year to $59.7 million; the trailing twelve-month figure through Mar 2026 stood at -$147.2 million (down 122.5% YoY), and the FY2025 full-year result was $438.3 million, down 26.53% from the prior year.
• EBITDA for Q1 2026 stood at $59.7 million, up from -$415.4 million in the prior quarter.
• The five-year high for EBITDA was $196.5 million in Q1 2025, with the low at -$415.4 million in Q4 2025.
• Historically, EBITDA has averaged $86.2 million across 5 years, with a median of $113.4 million in 2023.
• Annual changes were most pronounced in 2023 — EBITDA jumped 149.78% — and 2025, when it sank 352.98%.
• Encompass Health's EBITDA stood at $184.3 million in 2022, then slumped by 52.47% to $87.6 million in 2023, then soared by 87.44% to $164.2 million in 2024, then slumped by 352.98% to -$415.4 million in 2025, then jumped by 114.37% to $59.7 million in 2026.
• The last three EBITDA figures came in at $59.7 million (Q1 2026), -$415.4 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.